Atorvastatin vs GEMFIBROZIL

Compare Atorvastatin (Lipitor) and GEMFIBROZIL (Gemfibrozil) — clinical data, side effects, and patient experiences.

Atorvastatin

Lipitor · HMG-CoA Reductase Inhibitor (Statin)

How it works

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL-cholesterol ...

Approved for

Hyperlipidemia

Primary prevention of cardiovascular disease

Secondary prevention post-ACS

t½: 14 hoursFDA: 1996OralTablet

GEMFIBROZIL

Gemfibrozil · Fibrate

How it works

Other agent

Approved for

000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1

000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1

000 and 2

000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1

OralTablet

Quick Comparison

AtorvastatinGEMFIBROZIL

Drug Class

HMG-CoA Reductase Inhibitor (Statin)

Fibrate

Route

Oral

Half-Life

14 hours

—

FDA Approved

1996

—

Pregnancy

—

Efficacy Rating

9.0/10

0.0/10

Tolerability

7.0/10

0.0/10

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Atorvastatin

Muscle Pain

1-10%

Joint Pain

1-10%

Diarrhea

1-10%

GEMFIBROZIL

Nausea

1-10%

Fatigue

1-10%

Drug Not Working

1-10%

Diarrhea

1-10%

Dizziness

1-10%

Weakness

1-10%

Shortness of Breath

1-10%

Headache

1-10%

FDA Warnings

Atorvastatin

Rhabdomyolysis risk (rare)
Hepatotoxicity — monitor LFTs
May increase HbA1c and fasting glucose

GEMFIBROZIL

The higher risk of clofibrate-treated subjects for gallbladder disease was confirmed
Noncoronary heart disease related mortality showed an excess in the group originally randomized to gemfibrozil primarily due to cancer deaths observed during the open-label extension
5 year follow-up (65 gemfibrozil versus 45 placebo noncoronary deaths)
5%) deaths attributed to cancer in the group originally randomized to gemfibrozil and 18 (0

Community Sentiment Analysis

Based on 24 Reddit discussions

Atorvastatin

positive

15 threads

GEMFIBROZIL

22%

positive

9 threads

Community-Reported Side Effects

% of discussions mentioning each side effect

Head-to-Head Ratings

Patient Real-World Experience

Based on 1 verified patient review

Atorvastatin (1)

GEMFIBROZIL (0)

Efficacy

9.0/100.0/10

Tolerability

7.0/100.0/10

Overall Satisfaction

8.0/100.0/10

Atorvastatin Side Effects

No data yet

GEMFIBROZIL Side Effects

No data yet

Avg. Duration

36 months

100% still taking

Avg. Duration

0 months

0% still taking

Atorvastatin vs GEMFIBROZIL: What You Should Know

Key Differences

Atorvastatin is a HMG-CoA Reductase Inhibitor (Statin), while GEMFIBROZIL belongs to the Fibrate class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.

Patient Experience

Atorvastatin has an average efficacy rating of 9.0/10 and tolerability of 7.0/10 across 1 patient review. Patient-reported outcomes provide real-world context beyond clinical trials, though individual responses to medication vary significantly..

Safety Considerations

Atorvastatin carries 3 FDA warnings. GEMFIBROZIL carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Atorvastatin vs Rosuvastatin→FENOFIBRATE vs GEMFIBROZIL→Atorvastatin vs SIMVASTATIN→Atorvastatin vs PITAVASTATIN→ALIROCUMAB vs Atorvastatin→Atorvastatin vs FENOFIBRATE→

Loading comparison data...

Atorvastatin vs GEMFIBROZIL

Compare Atorvastatin (Lipitor) and GEMFIBROZIL (Gemfibrozil) — clinical data, side effects, and patient experiences.

Atorvastatin

Lipitor · HMG-CoA Reductase Inhibitor (Statin)

How it works

Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL-cholesterol ...

Approved for

Hyperlipidemia

Primary prevention of cardiovascular disease

Secondary prevention post-ACS

t½: 14 hoursFDA: 1996OralTablet

GEMFIBROZIL

Gemfibrozil · Fibrate

How it works

Other agent

Approved for

000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1

000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1

000 and 2

000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1

OralTablet

Quick Comparison

AtorvastatinGEMFIBROZIL

Drug Class

HMG-CoA Reductase Inhibitor (Statin)

Fibrate

Route

Oral

Half-Life

14 hours

—

FDA Approved

1996

—

Pregnancy

—

Efficacy Rating

9.0/10

0.0/10

Tolerability

7.0/10

0.0/10

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Atorvastatin

Muscle Pain

1-10%

Joint Pain

1-10%

Diarrhea

1-10%

GEMFIBROZIL

Nausea

1-10%

Fatigue

1-10%

Drug Not Working

1-10%

Diarrhea

1-10%

Dizziness

1-10%

Weakness

1-10%

Shortness of Breath

1-10%

Headache

1-10%

FDA Warnings

Atorvastatin

Rhabdomyolysis risk (rare)
Hepatotoxicity — monitor LFTs
May increase HbA1c and fasting glucose

GEMFIBROZIL

The higher risk of clofibrate-treated subjects for gallbladder disease was confirmed
Noncoronary heart disease related mortality showed an excess in the group originally randomized to gemfibrozil primarily due to cancer deaths observed during the open-label extension
5 year follow-up (65 gemfibrozil versus 45 placebo noncoronary deaths)
5%) deaths attributed to cancer in the group originally randomized to gemfibrozil and 18 (0

Community Sentiment Analysis

Based on 24 Reddit discussions

Atorvastatin

positive

15 threads

GEMFIBROZIL

22%

positive

9 threads

Community-Reported Side Effects

% of discussions mentioning each side effect

Head-to-Head Ratings

Patient Real-World Experience

Based on 1 verified patient review

Atorvastatin (1)

GEMFIBROZIL (0)

Efficacy

9.0/100.0/10

Tolerability

7.0/100.0/10

Overall Satisfaction

8.0/100.0/10

Atorvastatin Side Effects

No data yet

GEMFIBROZIL Side Effects

No data yet

Avg. Duration

36 months

100% still taking

Avg. Duration

0 months

0% still taking

Atorvastatin vs GEMFIBROZIL: What You Should Know

Key Differences

Patient Experience

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.